Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale
Jupiter Neurosciences dropped late Wednesday. The stock had jumped earlier after the company said it plans to license PharmAla Biotech’s MDMA-based ALA-002 for U.S. use. A few hours after that announcement, Jupiter set terms for a $2 million stock sale. The shares reversed hard, erasing the day’s advance.
